Biologic drug survival in psoriasis: insights from a multi-center retrospective study in West Malaysia.

Biologic drug survival in Malaysian psoriasis patients reflects global trends, with Secukinumab demonstrating superior durability. Loss of efficacy and funding issues were key barriers to persistence. The findings emphasize the need for optimized treatment strategies with wider access to biological treatment.